New B7 Family Immune Checkpoint Proteins

New B7 Family Immune Checkpoint Proteins

Targeting immune checkpoint regulators such as programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has achieved notable benefits in a variety of cancers. Recently five new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7, were identified, all of them possibly being of high interest in immunotherapy research.

B7-H3 [CD276] has a co-inhibitory function on T cells. Its expression on either tumour cells or diffuse tumour vasculature is significantly associated with an increased risk of death and bad outcome. Targeting B7-H3 not only enhances anti-tumour immunity but also inhibits tumour angiogenesis.

B7-H4 plays a significant role in the “immune escape” of tumours and is a potential therapeutic target for the treatment of cancer. It plays an important role in the T cell-mediated immune response as a negative regulator. The ligation of B7-H4 to unidentified receptors results in the inhibition of TCR-mediated T cell proliferation, cell-cycle progression and IL-2 production.

VISTA [V-domain immunoglobulin suppressor of T cell Activation; B7-H5] is type I Ig membrane protein homologous to PD-L1. VISTA is mainly expressed on hematopoietic tissues (spleen, thymus and bone marrow) and on myeloid cells. VISTA is a new negative checkpoint regulator that potently suppresses T cell activation. It delivers a co-inhibitory impact on T cell response.  Recent publications have reported that a recombinant VISTA protein needs to be multimerized to be active as a soluble ligand. The protein VISTA (mouse):COMP (mouse) (with the extracellular domain of mouse VISTA fused to the pentamerisation domain from the cartilage oligomeric matrix protein (COMP), but not VISTA-Fc, has been shown to function as an immunosuppressive agonist in vivo inhibiting the proliferation of CD4+ T cells. Additionally, a new function of the protein P-selectin glycoprotein ligand-1 (PSGL-1) as a new receptor for the immune checkpoint VISTA has been shown. Multimer VISTA binds PSGL-1 expressed on leukocytes at acidic pH, but not at the physiological pH 7. VISTA – PSGL-1 interaction shows that immune response can be regulated by acidic environments found in tumours.

B7-H6 (also known as NCR3LG1) is a ligand for NK cell activating receptor NKp30. It is expressed on tumour cells but can also be induced by inflammatory stress in healthy cells. B7-H6 has been validated as a potential target for antitumour immunotherapy strategies in tumour-bearing mice. The expression of B7-H6 is significantly correlated with post-operative prognosis in cancer patients and with distant metastasis status.

B7-H7 is widely expressed in human malignancies and its expression is associated with poor prognostic factors. Targeting B7-H7 not only benefits antitumour immunity but also inhibits tumour angiogenesis. For B7-H7, a T cell co-inhibitory role and a co-stimulatory role have been reported, most probably based on two counter receptors, one CD28H and the other unknown.

LIT: New B7 family checkpoints in human cancers: L. Ni & C. Dong; Mol. Cancer Ther. 16, 1203 (2017) • VISTA.COMP – an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses: A. Prodeus, et al.; JCI Insight 2, e94308 (2017)

NEW VISTA is an acidic pH-selective Ligand for PSGL-1 

PSGL-1 (human):Fc (human) (rec.) (Prod. No. AG-40B-0190) binds to its ligand VISTA only at acidic pH.

Method: VISTA (human):COMP (mouse) (rec.) (His) (Prod. No. AG-40B-0183) or an unrelated protein Nampt (human) (His) (Prod. No. AG-40A-0031Y)(Control) is coated on an ELISA plate at 1μg/ml overnight at room temperature. PSGL-1 (human):Fc (human) (rec) (Prod. No. AG-40B-0190) is incubated (starting at 1000ng/ml with a twofold serial dilution) for one hour in mild acidic (pH 6.4) or neutral conditions (pH 7.4) and then detected using an anti-human Fc antibody (HRP).

NEW: B7-H3 (human) ELISA Kit  – Biomarker for Immuno-Oncology Research

The B7-H3 (human) ELISA Kit (Prod. No. AG-45B-0025) is a sandwich ELISA for specific quantitative determination of soluble human B7-H3 (CD276) in serum, plasma and cell culture supernatants. Soluble human B7-H3 (CD276) is ectopically expressed in various cancers and its levels in serum of patients with cancer suggests it can be used as a noninvasive biomarker for diagnosis, prognosis and/or treatment response.

Biologically Active New B7 Family Proteins  

See all Biologically Active New B7-H3 proteins here.

See all Biologically Active New B7-H4 proteins here.

See all Biologically Active New B7-H5 proteins from Chimerigen and AdipoGen Life Sciences.

See all Biologically Active New B7-H6 proteins here.

Originally posted on adipogen.com/new-b7-family-immune-checkpoint-proteins/

Caltag Medsystems is the distributor of Adipogen products in the UK and Ireland. If you have any questions about these products, please contact us.

New B7 Family Immune Checkpoint Proteins
Tagged on:         

Contact us